ES2393849T7 - Compuestos de piperidina puenteada, de tipo quinoxalina sustituida, y usos de los mismos - Google Patents
Compuestos de piperidina puenteada, de tipo quinoxalina sustituida, y usos de los mismos Download PDFInfo
- Publication number
- ES2393849T7 ES2393849T7 ES09786064.7T ES09786064T ES2393849T7 ES 2393849 T7 ES2393849 T7 ES 2393849T7 ES 09786064 T ES09786064 T ES 09786064T ES 2393849 T7 ES2393849 T7 ES 2393849T7
- Authority
- ES
- Spain
- Prior art keywords
- term
- compound
- piperidine compounds
- substituted quinoxaline
- bridged piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
Description
EP 2324013 B3
E09786064
12-01-2015
- [0256]
- El término "EtOH" significa etanol, es decir alcohol etílico.
- 5
- [0257] El término "Et2O" significa éter dietílico, es decir, etoxietano.
- [0258]
- El término "THF" significa tetrahidrofurano.
- [0259]
- El término "DMF" significa N,N-dimetilformamida.
- 10
- [0260] El término "DCM" significa cloruro de metileno, es decir, diclorometano o CH2Cl2.
- [0261]
- El término "DCE" significa dicloroetano, es decir, 1,1-dicloroetano.
- 15
- [0262] El término "EtOAc" significa acetato de etilo.
- [0263]
- El término "MeCN" significa acetonitrilo.
- [0264]
- El término "DME" significa dimetoxietano, es decir, 1,2-dimetoxietano.
- 20
- [0265] El término "DMSO" significa dimetilsulfóxido, es decir, metilsulfinilmetano.
- [0266]
- El término "AcOH" significa ácido acético.
- 25
- [0267] El término "TEA" significa trietilamina.
- [0268]
- El término "NaH" significa hidruro sódico.
- [0269]
- El término "TsOH" significa ácido p-toluensulfónico, es decir, ácido toluen-4-sulfónico.
- 30
- [0270] El término "DPPA" significa fosforazidato de difenilo, es decir, azida de difenil-fosforilo.
- [0271]
- El término "TFA" significa ácido trifluoroacético, es decir, ácido 2,2,2-trifluoroacético.
- 35
- [0272] El término "TFAA" significa anhídrido trifluoroacético, es decir, anhídrido 2,2,2-trifluoroacético.
- [0273]
- El término "Bn" significa bencilo, es decir
.
[0274] El término "BOC" significa tert-butiloxicarbonilo, es decir
O
.
40 [0275] El término "CBZ" significa benciloxicarbonilo, es decir
- [0276]
- El término “IBD” significa enfermedad inflamatoria intestinal.
- 45
- [0277] El término “IBS” significa síndrome del intestino irritable.
- [0278]
- El término “ALS” significa esclerosis lateral amiotrófica.
36
EP 2324013 B3
E09786064
12-01-2015
Esquema F
5 [0285] El compuesto A4 y 2-oxomalonato de dietilo se pueden disolver en un disolvente con un punto de ebullición alto, tal como tolueno o xileno, y se calientan bajo condiciones de reflujo con eliminación azeotrópica de agua, para proporcionar el compuesto F1. El compuesto F1 se puede hidrolizar al ácido carboxílico F2 a través de tratamiento con una base, tal como NaOH acuoso, en un disolvente bajo condiciones adecuadas, tal como MeOH o EtOH, a una temperatura entre aproximadamente 0ºC y aproximadamente 25ºC. Una vez que se completa la hidrólisis, la mezcla de
10 reacción se neutraliza, por ejemplo, con HCl diluido, para proporcionar el compuesto F2.
O imagen41 NH2
NH4 + HCO2 ,Catalizador (Lit8)
ANB ANB
CH3 CH3
1) NH2OH 2) Reducción(Lit9)
NH2
CH3
H3
15 En el Esquema H y los otros esquemas, "Lit 8" se refiere a "A Modified Paladio Catalyzed Reductive Amination Procedure", de M. Allegretti et al., Tetrahedron Let., 58:5669-5674 (2002) y "Lit 9” se refiere a "Molecular Features Associated with Polyamina Modulation of NMDA Receptors", de A.H. Lewin et al., J. Med. Chem. 41:988-995 (1998).
[0286] El compuesto de Fórmula H1, en donde los grupos sustituyentes A y B forman juntos un puente, por ejemplo,
20 un puente de dos carbonos, se encuentra disponible comercialmente o se puede preparar por métodos conocidos en la técnica.
[0287] Cuando los grupos sustituyentes A y B forman juntos un puente, por ejemplo, un puente de dos carbonos, el compuesto H1 se puede convertir en el compuesto H2, el isómero "endo", bajo condiciones de aminación reductiva por 25 medio del uso de, por ejemplo, formiato de amonio y un catalizador de metal noble, por ejemplo, paladio sobre carbono, en un disolvente, tal como EtOH o MeOH, según se ha descrito en referencia a "Lit 8”. De forma similar, cuando los grupos sustituyentes A y B forman juntos un puente, por ejemplo, un puente de dos carbonos, el compuesto H1 se puede hacer reaccionar con hidroxilamina acuosa, en un disolvente, tal como hexanos, para formar una hidroxilamina intermedia, que se puede convertir en su oxima por deshidratación en un disolvente con un punto de ebullición alto, tal
30 como tolueno, bajo condiciones de Dean-stark. El intermedio oxima se puede convertir en el compuesto H3, el isómero "exo", mediante reducción, por medio del uso de, por ejemplo, sodio en propanol, tal como se ha descrito en referencia a "Lit 9”.
38
EP 2324013 B3
E09786064
12-01-2015
como NaOH acuoso, en un disolvente adecuado, tal como MeOH o EtOH, seguido por neutralización, utilizando un ácido, tal como HCl diluido.
5
[0289] El compuesto I4 se puede preparar, tal como se muestra en el Esquema L, a partir del compuesto A1 (de manera similar a las etapas descritas en el Esquema A). Cuando los grupos sustituyentes A y B del compuesto I4 forman un puente, por ejemplo, un puente de dos carbonos, los dos isómeros, "exo" y "endo”, se pueden separar por
10 cromatografía y se pueden convertir por separado en compuestos tales como F1, F2, y similares según se ha descrito previamente en el Esquema F. Esquema N
OOO O
OH
N4
PBr3
O
Br
N5
40
EP 2324013 B3
E09786064
12-01-2015
[0373] A una mezcla del compuesto de fórmula QA ((exo)-biciclo[3.3.1]nonan-3-amina, 1.222 mg, 8,78 mmol), K2CO3 (121,3 mg, 0,878 mmol), EtOH (10 mL), y agua (3 mL) a una temperatura de aproximadamente 25°C se adicionó 5 una mezcla del compuesto de fórmula LB (2.846 mg, 8,78 mmol), EtOH (14mL), y agua (16 mL). Después de la adición, la mezcla de reacción resultante se calentó a una temperatura de 90°C y se agitó durante 4 horas. Después de ello, la mezcla de reacción se enfrió a una temperatura de aproximadamente 25°C y se vertió hielo-agua (50 mL) en la mezcla de reacción para proporcionar un precipitado incoloro. Al precipitado se le adicionó NaHCO3 acuoso saturado (10 mL). La mezcla se sonicó; se formó un precipitado. El precipitado se filtró, se lavó dos veces con agua (8 mL por cada
10 lavado), y se secó a 70°C durante 8 horas bajo presión reducida para proporcionar 1.020 mg del compuesto de fórmula OB en forma de un sólido incoloro (rendimiento 45%).
[0374] La identidad del compuesto de fórmula QB, 9-((exo)-biciclo[3.3.1]nonan-3-il)-9-azabiciclo[3.3.1]nonan-3-ona, se confirmó utilizando 1H NMR y LC/MS.
15 [0375] Compuesto QB: 1H NMR: H (400MHz, CDCl3): 1,26 (s, 1H), 1,43-1,69 (m, 13H), 1,85 (m, 2H), 2,01 (m, 4H), 2,22 (d, 2H), 2,63 (dd, J=16,42, 6,32Hz, 2H), 3,35-3,41 (m, 1H), 3,69 (s, 2H); LC/MS: m/z=262,1 [M+H]+ (Calc: 261).
[0376] Bajo una atmósfera de nitrógeno, a una solución del compuesto de fórmula QB (1 1.020 mg, 3,90 mmol) en
20 CH2Cl2 (15 mL) a una temperatura de aproximadamente 25°C se adicionó 1,2-fenilendiamina (1.266 mg, 11,71 mmol, Sigma-Aldrich) y ácido 2-etilhexanoico (0,938 mL, 5,85 mmol, Sigma-Aldrich). La mezcla se agitó a una temperatura de aproximadamente 25°C durante 30 minutos para proporcionar mezcla de reacción 1.
[0377] Bajo una atmósfera de nitrógeno, a una solución de tetrahidroborato de sodio (590 mg, 15,61 mmol, Sigma25 Aldrich) en CH2Cl2 (10mL) a una temperatura de aproximadamente 25°C se adicionó ácido 2-etilhexanoico (8,75 mL,
56
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8248208P | 2008-07-21 | 2008-07-21 | |
US82482 | 2008-07-21 | ||
US82482P | 2008-07-21 | ||
PCT/IB2009/006356 WO2010010458A1 (en) | 2008-07-21 | 2009-07-20 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2393849T3 ES2393849T3 (es) | 2012-12-28 |
ES2393849T7 true ES2393849T7 (es) | 2015-01-28 |
Family
ID=41077776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09786064.7T Active ES2393849T7 (es) | 2008-07-21 | 2009-07-20 | Compuestos de piperidina puenteada, de tipo quinoxalina sustituida, y usos de los mismos |
Country Status (32)
Country | Link |
---|---|
US (6) | US8476271B2 (es) |
EP (2) | EP2324013B3 (es) |
JP (1) | JP5416210B2 (es) |
KR (1) | KR101333660B1 (es) |
CN (1) | CN102105465B (es) |
AR (1) | AR072578A1 (es) |
AU (1) | AU2009275218C1 (es) |
BR (1) | BRPI0911031B8 (es) |
CA (1) | CA2730288C (es) |
CL (1) | CL2011000148A1 (es) |
CO (1) | CO6341627A2 (es) |
CY (1) | CY1113485T1 (es) |
DK (1) | DK2324013T6 (es) |
ES (1) | ES2393849T7 (es) |
HK (1) | HK1157763A1 (es) |
HR (1) | HRP20120841T4 (es) |
IL (2) | IL210549A (es) |
MX (1) | MX2011000872A (es) |
MY (1) | MY153948A (es) |
NZ (1) | NZ590416A (es) |
PE (2) | PE20140102A1 (es) |
PL (1) | PL2324013T6 (es) |
PT (1) | PT2324013E (es) |
RS (1) | RS52590B2 (es) |
RU (1) | RU2500678C2 (es) |
SG (1) | SG192539A1 (es) |
SI (1) | SI2324013T1 (es) |
SM (1) | SMT201200053B (es) |
TW (2) | TWI432434B (es) |
UA (1) | UA99540C2 (es) |
WO (1) | WO2010010458A1 (es) |
ZA (1) | ZA201100189B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5462784B2 (ja) | 2007-04-27 | 2014-04-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | Trpv1アンタゴニストとその使用 |
TWI448289B (zh) | 2007-08-31 | 2014-08-11 | Purdue Pharma Lp | 經取代之喹啉型哌啶化合物及其用途 |
UA99540C2 (ru) | 2008-07-21 | 2012-08-27 | Пердью Фарма Л.П. | Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение |
AU2011346749A1 (en) | 2010-12-22 | 2013-05-02 | Purdue Pharma L.P. | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof |
PT2723732T (pt) | 2011-06-22 | 2017-02-17 | Purdue Pharma Lp | Antagonistas de trpv1 incluindo substituinte di-hidroxilo e suas utilizações |
US9394293B2 (en) | 2011-08-10 | 2016-07-19 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
EP2797912B1 (en) * | 2011-12-01 | 2016-05-25 | Purdue Pharma L.P. | Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof |
US9085561B2 (en) | 2012-07-30 | 2015-07-21 | Purdue Pharma L.P. | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators |
US9090618B2 (en) | 2012-12-27 | 2015-07-28 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
WO2014102588A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Indole and indoline-type piperidine compounds and uses thereof |
WO2014102590A1 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
WO2014102592A2 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof |
JOP20190008A1 (ar) * | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
EP3743049A1 (en) * | 2018-01-24 | 2020-12-02 | Purdue Pharma LP | Sleep disorder treatment and prevention |
MX2021008039A (es) * | 2019-01-31 | 2021-08-05 | Purdue Pharma Lp | Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido. |
EP4340837A1 (en) * | 2021-05-21 | 2024-03-27 | Purdue Pharma L.P. | Methods of treating interstitial cystitis/bladder pain syndrome |
WO2023250190A1 (en) * | 2022-06-24 | 2023-12-28 | Purdue Pharma L.P. | Methods of treating or preventing overactive bladder syndrome |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5225402A (en) | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US20020061554A1 (en) | 1992-08-13 | 2002-05-23 | Evans Christopher J. | Orphan opioid receptor and recombinant materials for its production |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
AU691829B2 (en) | 1993-07-16 | 1998-05-28 | Merck & Co., Inc. | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
ATE301457T1 (de) | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
JP3776201B2 (ja) | 1997-04-17 | 2006-05-17 | 株式会社リコー | 光記録媒体 |
WO1998054168A1 (fr) | 1997-05-30 | 1998-12-03 | Banyu Pharmaceutical Co., Ltd. | Derives de 2-0xoimidazole |
WO1999011632A1 (fr) | 1997-09-01 | 1999-03-11 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide quinoxalinecarboxylique disubstitues en position 6,7-asymetrique, sels d'addition de ces derives, et procedes de preparation de ces derives et de ces sels |
SE9800836D0 (sv) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
DE69943144D1 (de) | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
EP1068190A1 (en) | 1998-03-31 | 2001-01-17 | Warner-Lambert Company Llc | Quinoxalinones as serine protease inhibitors such as factor xa and thrombin |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
AU1948601A (en) | 1999-12-06 | 2001-06-12 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
AU1816901A (en) | 1999-12-06 | 2001-06-12 | Euro-Celtique S.A. | Benzimidazole compounds having nociceptin receptor affinity |
AU6594401A (en) | 2000-05-24 | 2001-12-03 | Bayer Aktiengesellschaft | 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines |
HUP0401109A3 (en) | 2001-04-18 | 2007-12-28 | Euro Celtique Sa | Nociceptin analogs, their use and pharmaceutical compositions containing them |
ES2316559T3 (es) | 2001-04-18 | 2009-04-16 | Euro-Celtique S.A. | Compuestos espiroindeno y espiroindano. |
DK1975164T3 (da) | 2001-04-18 | 2010-05-25 | Euro Celtique Sa | Octahydrobenzimidazolon-forbindelser som analgetika |
KR100729242B1 (ko) | 2001-04-18 | 2007-06-15 | 유로-셀티크 소시에떼 아노뉨 | 노시셉틴 유사체 |
CA2444634C (en) | 2001-04-18 | 2011-06-07 | R. Richard Goehring | Spiropyrazole compounds |
US6930104B2 (en) | 2001-04-26 | 2005-08-16 | Takeda Chemical Industries, Ltd. | Heterocyclic derivatives |
DE10123163A1 (de) | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
WO2002094790A1 (fr) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
AR037211A1 (es) * | 2001-11-07 | 2004-10-27 | Schering Corp | Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1 |
JPWO2003062234A1 (ja) | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
EP1491212B1 (en) | 2002-03-29 | 2012-08-08 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
US20110092704A1 (en) | 2002-10-17 | 2011-04-21 | Parvis Gharagozloo | Preparation of triazospiro compounds |
DE10343098A1 (de) | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
US8067603B2 (en) | 2003-09-25 | 2011-11-29 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |
US20050228023A1 (en) | 2003-12-19 | 2005-10-13 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
DE10360793A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
EP1711484A4 (en) | 2004-02-03 | 2007-06-20 | Euro Celtique Sa | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES |
DE102004023332A1 (de) | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
EP1676843A1 (en) | 2004-12-31 | 2006-07-05 | Nikem Research S.R.L. | Substituted indole ligands for the ORL-1 receptor |
KR20080012976A (ko) | 2005-06-17 | 2008-02-12 | 화이자 인코포레이티드 | Orl1-수용기 길항제로서의 알파-(아릴- 또는헤테로아릴-메틸)-베타-피페리디노 프로판아마이드 화합물 |
US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
PE20071159A1 (es) * | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
TW200815405A (en) | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
EP1873150A1 (en) | 2006-06-30 | 2008-01-02 | Nikem Research S.R.L. | Fluorinated indoleamides useful as ligands of the ORL-1 receptor |
ES2353448T3 (es) * | 2007-01-16 | 2011-03-02 | Purdue Pharma L.P. | Piperidinas heterocíclico-sustituidas como ligandos de orl-1. |
AU2008219980B2 (en) | 2007-03-01 | 2012-01-12 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
TWI448289B (zh) * | 2007-08-31 | 2014-08-11 | Purdue Pharma Lp | 經取代之喹啉型哌啶化合物及其用途 |
JP2011528369A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | 二環式ヘテロ環誘導体およびそれらの使用方法 |
UA99540C2 (ru) | 2008-07-21 | 2012-08-27 | Пердью Фарма Л.П. | Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение |
-
2009
- 2009-07-20 UA UAA201102051A patent/UA99540C2/ru unknown
- 2009-07-20 PT PT97860647T patent/PT2324013E/pt unknown
- 2009-07-20 AU AU2009275218A patent/AU2009275218C1/en active Active
- 2009-07-20 EP EP20090786064 patent/EP2324013B3/en active Active
- 2009-07-20 RS RS20120549A patent/RS52590B2/sr unknown
- 2009-07-20 DK DK09786064T patent/DK2324013T6/en active
- 2009-07-20 CA CA2730288A patent/CA2730288C/en active Active
- 2009-07-20 ES ES09786064.7T patent/ES2393849T7/es active Active
- 2009-07-20 EP EP20120184703 patent/EP2537844A1/en not_active Withdrawn
- 2009-07-20 WO PCT/IB2009/006356 patent/WO2010010458A1/en active Application Filing
- 2009-07-20 PE PE2013001724A patent/PE20140102A1/es not_active Application Discontinuation
- 2009-07-20 RU RU2011106375/04A patent/RU2500678C2/ru active
- 2009-07-20 JP JP2011519251A patent/JP5416210B2/ja active Active
- 2009-07-20 PL PL09786064T patent/PL2324013T6/pl unknown
- 2009-07-20 KR KR1020117003975A patent/KR101333660B1/ko active IP Right Grant
- 2009-07-20 NZ NZ59041609A patent/NZ590416A/xx unknown
- 2009-07-20 SI SI200930372T patent/SI2324013T1/sl unknown
- 2009-07-20 SG SG2013055405A patent/SG192539A1/en unknown
- 2009-07-20 PE PE2011000058A patent/PE20110416A1/es active IP Right Grant
- 2009-07-20 AR ARP090102759 patent/AR072578A1/es active IP Right Grant
- 2009-07-20 MY MYPI2010006240A patent/MY153948A/en unknown
- 2009-07-20 BR BRPI0911031A patent/BRPI0911031B8/pt active IP Right Grant
- 2009-07-20 CN CN200980128684.0A patent/CN102105465B/zh active Active
- 2009-07-20 MX MX2011000872A patent/MX2011000872A/es active IP Right Grant
- 2009-07-21 TW TW102104550A patent/TWI432434B/zh active
- 2009-07-21 TW TW98124571A patent/TW201016697A/zh unknown
-
2011
- 2011-01-06 ZA ZA2011/00189A patent/ZA201100189B/en unknown
- 2011-01-10 IL IL210549A patent/IL210549A/en active IP Right Grant
- 2011-01-20 US US13/010,632 patent/US8476271B2/en active Active
- 2011-01-21 CL CL2011000148A patent/CL2011000148A1/es unknown
- 2011-02-18 CO CO11019525A patent/CO6341627A2/es not_active Application Discontinuation
- 2011-11-09 HK HK11112119A patent/HK1157763A1/xx unknown
-
2012
- 2012-10-19 HR HRP20120841TT patent/HRP20120841T4/hr unknown
- 2012-11-28 SM SM201200053T patent/SMT201200053B/it unknown
- 2012-12-12 CY CY20121101216T patent/CY1113485T1/el unknown
-
2013
- 2013-06-11 US US13/915,204 patent/US9145408B2/en active Active
-
2015
- 2015-09-18 US US14/859,139 patent/US9890164B2/en active Active
-
2017
- 2017-08-30 IL IL254218A patent/IL254218A0/en unknown
-
2018
- 2018-01-23 US US15/878,142 patent/US20180148449A1/en not_active Abandoned
- 2018-09-04 US US16/120,837 patent/US10519156B2/en active Active
-
2019
- 2019-12-06 US US16/705,814 patent/US11111246B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2393849T7 (es) | Compuestos de piperidina puenteada, de tipo quinoxalina sustituida, y usos de los mismos | |
ES2380098T3 (es) | Procedimiento de preparación de una piperidina disustituida y productos intermedios | |
ES2864009T3 (es) | 5-Fluoro-1H-pirazolopiridinas sustituidas en forma cristalina | |
AU2018354972B2 (en) | An improved process for the preparation of ribociclib and its salts | |
US9745267B2 (en) | Compounds as modulators of RORC | |
JP2017507934A (ja) | ビルダグリプチンのための新規な実用的プロセス | |
Huang et al. | A facile approach to trans-4, 5-pyrrolidine lactam and application in the synthesis of nemonapride and streptopyrrolidine | |
WO2018150327A1 (en) | Crisaborole production process | |
ES2456866T3 (es) | Procedimiento para la obtención de 3,3-difenilpropilaminas | |
US20220356194A1 (en) | Process for preparing benzothiophen-2yl boronate | |
ES2663389T3 (es) | Procedimiento de preparación de los inhibidores de dipeptidilpeptidasa | |
CA2719526A1 (en) | Conversion of tryptophan into .beta.-carboline derivatives | |
US8940749B2 (en) | Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydor-9-hydroxy-2-methyl-4H-pyrido[ 1, 2-A]-pyrimidin-4-one(paliperidone) and paliperidone palmitate | |
IL107394A (en) | Process for the preparation of metal complexes of tetraazacycloalkane derivatives | |
ES2386678T3 (es) | Procedimiento de preparación de 4'-[[4-metil-6-(1-metil-1H-bencimidazol-2-il)-2-propil-1H-bencimidazol-1il]metil]bifenil-2-carboxílico (telmisartán) | |
US20160332977A1 (en) | Processes for preparing fused heterocyclic ion channel modulators | |
WO2023214935A1 (en) | Process for preparing relugolix and intermediates thereof | |
CA2960473A1 (en) | Processes for the preparation of tadalafil and intermediates thereof | |
CN106795174B (zh) | 一种抗病毒活性双氮氧杂环螺二酮哌嗪生物碱衍生物及其制备方法 | |
CN110627768B (zh) | 一种莫西沙星降解杂质j的制备方法 | |
US20220056053A1 (en) | Synthesis of crac channel inhibitors | |
CA3163243A1 (en) | Sstr5 antagonists | |
CN107383058B (zh) | 马波沙星的制备 | |
JP2011522042A (ja) | タダラフィルの製造方法 | |
US20230416243A1 (en) | Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof |